卡培他滨在治疗转移性乳腺癌中作用的Meta分析

摘要/Abstract

摘要： 目的: 近年来关于卡培他滨在治疗转移性乳腺癌上的研究结论并不一致,现采用Meta分析的方法评价卡培他滨在治疗转移性乳腺癌中的疗效及不良反应。方法: 计算机检索2014年3月以前Cochrane、Pubmed、EMbase、Medline、中国生物医学文献数据库、中国知网、万方数据库的相关文献,根据严格的纳入和排除标准,筛选出加入卡培他滨的化疗方案对比不加卡培他滨的化疗方案的随机或半随机对照试验,最终将数据通过Revman 5.2 软件合并及分析。质量评价采用 Cochrane Handbook 5.0.1 的评价方法。结果: 总共纳入9个随机临床对照实验及1个半随机对照试验,共1 449例患者进行Meta分析,结果显示,联合卡培他滨的化疗方案对比不加入卡培他滨的方案,可以提高总反应率(RR=1.61; 95%CI:1.29~2.02,P<0.0001)及完全反应率(RR=1.68;95%CI:1.04~2.71, P<0.03),减少肌痛和骨髓抑制的几率,但同时会增加胃肠道反应和手足综合征的发生概率。两组方案在部分反应率和其余不良反应上尚不能认为有差异。结论: 联合卡培他滨的化疗方案在治疗转移性乳腺癌的作用上,可以提高总反应率及完全反应率,但是治疗过程中应注意防治胃肠道反应及手足综合征等不良反应。

关键词: 卡培他滨, 转移性乳腺癌, Meta分析

Abstract: AIM: In recent years, the conclusion about the efficacy and toxicity of capecitabine in the chemotherapy of metastatic breast cancer was discordant. This Meta analysis was to ascertain the efficacy and toxicity of capecitabine in metastatic or advanced breast cancer.METHODS: By searching the Cochrane, Pubmed, EMbase, Medline, CBM, CNKI, Wanfang databases, randomized controlled trials (RCTs) and quasi-RCTs about chemotherapy with or without capecitabine before March 2014 were included. Date were merged and analysed by RevMan 5.2.RESULTS: Nine RCTs and one quasi-RCT involving 1 449 patients with advanced or metastatic breast cancer were included. Results showed that the chemotherapy which included capecitabine had higher overall survival (OR)(RR=1.61;95%CI:1.29-2.02,P<0.0001), complete survival (CR)(RR=1.68;95%CI:1.04-2.71,P<0.03), gastrointestinal reaction, hand-foot syndrome rate and lower myalgia rate, myelotoxicity rate when compared with chemotherapy without capecitabine.CONCLUSION: This Meta analysis shows that chemotherapy which included capecitabine can increase the OR and CR in the metastatic or advance breast cancer. Correspondingly, people should pay more attention to some of the adverse events such as hand-foot syndrome.

Key words: capecitabine, breast cancer, Meta analysis

中图分类号:

兰柯, 李文翰, 徐子森, 党诚学. 卡培他滨在治疗转移性乳腺癌中作用的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(4): 425-429.

LAN Ke, LI Wen-han, XU Zi-sen, DANG Cheng-xue. Meta analysis on the efficacy of capecitabine in the chemotherapy of metastatic breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 425-429.

参考文献

[1] Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer[J]. Lancet Oncol, 2014, 15(2): e58-e68.
[2] Wang AT, Vachon CM, Brandt KR, et al. Breast density and breast cancer risk: a practical review[J]. Mayo Clin Proc, 2014, 89(4): 548-557.
[3] 朱益平,盛莉莉,路王,等. NX方案和GP方案治疗蒽环类及紫杉类药物治疗后复发转移乳腺癌的临床疗效分析[J]. 中国临床药理学与治疗学, 2013, 9(8): 918-924.
[4] 郝吉庆, 马强, 刘彭坤. 吉西他滨联合洛铂或顺铂治疗蒽环类和紫杉类药物耐药晚期乳腺癌的比较研究[J]. 中国临床药理学与治疗学, 2012, 17(5): 554-558.
[5] Daniele G, Gallo M, Piccirillo MC, et al. Pharmacokinetic evaluation of capecitabine in breast cancer[J]. Expert Opin Drug Metab Toxicol, 2013, 9(2): 225-235.
[6] Bonotto M, Bozza C, Di Loreto C, et al. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase[J]? Clin Breast Cancer, 2013, 13(3): 167-172.
[7] O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results[J]. J Clin Oncol, 2002, 20(12): 2812-2823.
[8] 李明毅,林大任,谭洁媚. 卡培他滨联合多西紫杉醇治疗蒽环类耐药的转移性乳腺癌31例[J]. 中华肿瘤防治杂志, 2006, 8(3): 216-217.
[9] 吴慧娟,刘涛,邹宏志. 多西紫杉醇卡培他滨治疗蒽环类耐药的乳腺癌研究[J]. 医药论坛杂志, 2007, 6(16): 59-60.
[10]Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983.
[11]赵韬,邵清,张汀荣,等. 希罗达在转移性乳腺癌维持治疗中的疗效观察[J]. 实用临床医药杂志, 2011, 7(7): 88-90.
[12]张明帅,张国庆,欧江华,等. 唑来磷酸联合卡培他滨治疗乳腺癌多发骨转移临床疗效研究[J]. 中国全科医学, 2011, 8(35): 4103-4105.
[13]Hatschek T, Carlsson L, Einbeigi Z, et al. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial[J]. Breast Cancer Res Treat, 2012, 131(3): 939-947.
[14]蒋伟丰,汪永旭. 多西他赛联合卡培他滨治疗老年转移乳腺癌的临床观察[J]. 中国高等医学教育, 2012, 10(12): 133-146.
[15]孟秀敏. 多西他赛联合卡培他滨治疗紫杉醇耐药乳腺癌患者40例[J]. 中国药业, 2013, 10(17): 64-65.
[16]王淑芳,牛晓薇. 卡培他滨维持治疗在晚期三阴性乳腺癌治疗中的临床应用[J]. 中国社区医师(医学专业), 2013, 6(5): 138-139.
[17]Wang Y, Yang H, Wei J F, et al. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials[J]. Curr Med Res Opin, 2012, 28(12): 1911-1919.
[18]Mavroudis D, Papakotoulas P, Ardavanis A, et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer[J]. Ann Oncol, 2010, 21(1): 48-54.
[19]Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer[J]. J Clin Oncol, 2009, 27(11): 1753-1760.